Sector News

J&J, Takeda among interested in Brazil's Hypermarcas: sources

April 26, 2017
Life sciences

Johnson & Johnson, Novartis AG and Takeda Pharmaceutical Co Ltd have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA, two people with knowledge of the matter said on Monday.

The owners of investment vehicles Igarapava Participações SA and Maiorem SA de CV, which hold a combined 34 percent of Hypermarcas, hired Banco Bradesco SA and Credit Suisse Group AG to advise them on options for their stakes, including a sale, said the people.

According to one of the people, who requested anonymity because the matter is private, the purchase of the stakes that Brazilian billionaire João Alves Queiroz Filho and the Mexican family that own Igarapava and Maiorem, respectively, would automatically trigger a buyout of minority shareholders.

Shares of Hypermarcas closed 3.8 percent up at 30.35 reais on Monday, on optimism that a deal could boost the company’s $6 billion market value. The stock had extended gains after the Reuters report, rising more than 7 percent to an all-time high of 31.38 reais.

None of the potential bidders have yet delivered formal, binding proposals, one of the people said, noting that there is no certainty a deal will be struck.

In a securities filing, Hypermarcas was informed by the investors in those vehicles about “the inexistence of any attempts to sell their stakes in the company.” The banks and Takeda did not immediately have a comment.

J&J and Novartis declined to comment on market speculation.

Interest in Hypermarcas from foreign pharmaceutical behemoths comes after Brazil’s largest listed drug producer spent the past two years focusing on over-the-counter medicines. Hypermarcas raised some $1.5 billion from the sale of personal care brands to Coty Inc, Reckitt Benckiser Group Plc and Ontex Group NV.

O Globo columnist Lauro Jardim reported on Sunday, without citing how he obtained the information, that billionaire tycoon Queiroz and his family were discussing a potential sale of their stakes with a number of unidentified foreign companies.

By Tatiana Bautzer and Guillermo Parra-Bernal

Source: Reuters

comments closed

Related News

July 6, 2025

AbbVie to acquire Capstan Therapeutics for $2 Billion

Life sciences

AbbVie has announced it will acquire Capstan Therapeutics, a clinical-stage biotechnology company focused on advancing in vivo cell engineering through RNA delivery using targeted lipid nanoparticles (tLNPs). The deal includes Capstan’s lead drug candidate, an in vivo CAR-T therapy for autoimmune diseases that is currently in early-stage clinical trials.

July 6, 2025

Modella AI and AstraZeneca link for cancer clinical development

Life sciences

Modella AI has signed a multi-year agreement with AstraZeneca to expedite AI-driven oncology clinical development. The agreement will enable the use of Modella AI’s latest models, with rich feature extraction from different types of data, to speed up clinical development across AstraZeneca’s worldwide oncology portfolio.

July 6, 2025

Merck concludes SpringWorks acquisition for $3.4bn

Life sciences

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary closing conditions. Merck will add two SpringWorks’ products targeting rare tumours with limited treatment options.

How can we help you?

We're easy to reach